2023-10-27 カロリンスカ研究所(KI)
◆この研究は、長期COVIDが世界中の人々に影響を与えており、特に重症のCOVID-19経験者の身体症状を診断後2年間にわたって監視する必要性を強調しています。研究にはスウェーデン、デンマーク、ノルウェー、アイスランドの約65,000人の成人が参加し、COVID-19感染経験者の中で慢性的な身体症状の普及率が高かったことが示されました。
<関連情報>
- https://news.ki.se/long-covid-most-prevalent-in-the-most-seriously-ill
- https://www.sciencedirect.com/science/article/pii/S2666776223001758?via%3Dihub
COVID-19の重症度と身体症状の2年有病率:アイスランド、スウェーデン、ノルウェー、デンマークにおける観察研究 COVID-19 illness severity and 2-year prevalence of physical symptoms: an observational study in Iceland, Sweden, Norway and Denmark
Qing Shen, Emily E. Joyce, Omid V. Ebrahimi, Maria Didriksen, Anikó Lovik, Karen Sól Sævarsdóttir, Ingibjörg Magnúsdóttir, Dorte Helenius Mikkelsen, Anna Bára Unnarsdóttir, Arna Hauksdóttir, Asle Hoffart, Anna K. Kähler, Edda Björk Thórdardóttirl, Elías Eythórsson, Emma M. Frans, Gunnar Tómasson, Helga Ask, Hrönn Hardardóttir, Jóhanna Jakobsdóttir, Kelli Lehto…Unnur Anna Valdimarsdóttir
The Lancet Regional Health – Europe Available online 27 October 2023
DOI:https://doi.org/10.1016/j.lanepe.2023.100756
Summary
Background
Although the persistence of physical symptoms after SARS-CoV-2 infection is a major public health concern, evidence from large observational studies beyond one year post diagnosis remain scarce. We aimed to assess the prevalence of physical symptoms in relation to acute illness severity up to more than 2-years after diagnosis of COVID-19.
Methods
This multinational study included 64,880 adult participants from Iceland, Sweden, Denmark, and Norway with self-reported data on COVID-19 and physical symptoms from April 2020 to August 2022. We compared the prevalence of 15 physical symptoms, measured by the Patient Health Questionnaire (PHQ-15), among individuals with or without a confirmed COVID-19 diagnosis, by acute illness severity, and by time since diagnosis. We additionally assessed the change in symptoms in a subset of Swedish adults with repeated measures, before and after COVID-19 diagnosis.
Findings
During up to 27 months of follow-up, 34.5% participants (22,382/64,880) were diagnosed with COVID-19. Individuals who were diagnosed with COVID-19, compared to those not diagnosed, had an overall 37% higher prevalence of severe physical symptom burden (PHQ-15 score ≥15, adjusted prevalence ratio [PR] 1.37 [95% confidence interval [CI] 1.23–1.52]). The prevalence was associated with acute COVID-19 severity: individuals bedridden for seven days or longer presented with the highest prevalence (PR 2.25 [1.85–2.74]), while individuals never bedridden presented with similar prevalence as individuals not diagnosed with COVID-19 (PR 0.92 [0.68–1.24]). The prevalence was statistically significantly elevated among individuals diagnosed with COVID-19 for eight of the fifteen measured symptoms: shortness of breath, chest pain, dizziness, heart racing, headaches, low energy/fatigue, trouble sleeping, and back pain. The analysis of repeated measurements rendered similar results as the main analysis.
Interpretation
These data suggest an elevated prevalence of some, but not all, physical symptoms during up to more than 2 years after diagnosis of COVID-19, particularly among individuals suffering a severe acute illness, highlighting the importance of continued monitoring and alleviation of these targeted core symptoms.
Funding
This work was mainly supported by grants from NordForsk (COVIDMENT, grant number 105668 and 138929) and Horizon 2020 (CoMorMent, 847776). See Acknowledgements for further details on funding.
